BRAF突变非小细胞肺癌的分子图谱:克隆性与驱动突变相关并识别可靶向的非V600驱动突变
该研究利用Guardant360数据库对BRAF突变NSCLC进行整合分析,共识别305个独特BRAF突变,其中45%为意义未知变异。已知功能突变(1-3类)克隆性高于未知类别突变(p<0.01),F468S和N581Y为新发现激活突变。部分非V600突变患者对MEK/BRAF抑制剂有响应,提示基因组图谱与药物敏感性整合可指导治疗。
要点
- BRAF突变NSCLC中45%为意义未知变异,克隆性分析有助于识别潜在致癌驱动。
- F468S和N581Y被鉴定为新激活突变,扩展了BRAF突变谱。
- 部分非V600突变(如L597R)对MEK/BRAF抑制剂有持久响应,而G469V和D594G无响应。
核心结论
- BRAF突变NSCLC中已知功能突变克隆性更高,可能帮助识别更可能为致癌驱动的意义未知变异。
- 某些非V600突变对MEK和BRAF抑制剂有响应,基因组图谱与药物敏感性整合可指导治疗。
研究设计与样本
- 利用Guardant360数据库中BRAF突变NSCLC的基因组图谱进行整合分析。
- 在Ba/F3模型中进行细胞活力测定,在NSCLC细胞系中进行药物筛选。
主要发现
- 共识别305个独特BRAF突变,错义突变最常见(276个,90%),45%为意义未知变异。
- F468S和N581Y被鉴定为新激活突变。
- 1至3类突变克隆性高于未知类别突变(p < 0.01)。
- 3例患者接受MEK抑制剂联合或不联合BRAF抑制剂治疗:G469V和D594G突变患者无响应,L597R突变患者有持久响应。
- Trametinib联合或不联合dabrafenib、LXH254和lifirafenib对BRAF非V600突变NSCLC细胞系的抑制比其他MEK、BRAF和ERK抑制剂更有效,与对BRAF V600E细胞系的抑制相当。
临床怎么用
- 对BRAF突变NSCLC进行克隆性分析可能有助于识别意义未知变异中的潜在驱动突变。
- 部分非V600突变(如L597R)可考虑MEK/BRAF抑制剂治疗,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Approximately 4% of NSCLC harbor BRAF mutations, and approximately 50% of these are non-V600 mutations. Treatment of tumors harboring non-V600 mutations is challenging because of functional heterogeneity and lack of knowledge regarding their clinical significance and response to targeted agents. METHODS: We conducted an integrative analysis of BRAF non-V600 mutations using genomic profiles of BRAF-mutant NSCLC from the Guardant360 database. BRAF mutations were categorized by clonality and class (1 and 2: RAS-independent; 3: RAS-dependent). Cell viability assays were performed in Ba/F3 models. Drug screens were performed in NSCLC cell lines. RESULTS: A total of 305 unique BRAF mutations were identified. Missense mutations were most common (276, 90%), and 45% were variants of unknown significance. F468S and N581Y were identified as novel activating mutations. Class 1 to 3 mutations had higher clonality than mutations of unknown class (p < 0.01). Three patients were treated with MEK with or without BRAF inhibitors. Patients harboring G469V and D594G mutations did not respond, whereas a patient with the L597R mutation had a durable response. Trametinib with or without dabrafenib, LXH254, and lifirafenib had more potent inhibition of BRAF non-V600-mutant NSCLC cell lines than other MEK, BRAF, and ERK inhibitors, comparable with the inhibition of BRAF V600E cell line. CONCLUSIONS: In BRAF-mutant NSCLC, clonality is higher in known functional mutations and may allow identification of variants of unknown significance that are more likely to be oncogenic drivers. Our data indicate that certain non-V600 mutations are responsive to MEK and BRAF inhibitors. This integration of genomic profiling and drug sensitivity may guide the treatment for BRAF-mutant NSCLC.
引用
- Negrao MV, Raymond VM, Lanman RB, et al. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. J Thorac Oncol. 2020. PMID: 32540409. doi:10.1016/j.jtho.2020.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。